If subject is not currently receiving a tricyclic antidepressant anticonvulsant and/or Class I antiarrhythmic e.g. amitriptyline mexiletine phenytoin gabapentin or carbamazepine for treatment of pain or any other condition subject must be willing and able to abstain from initiation of these agents within 4 weeks prior to randomization and throughout the study 